Johanna Maenpaa

4PUBLICATIONS
37CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Nov 26, 2024
Beyond HRD Status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer.

Maj K Kjeldsen, Morten Jørgensen, Dina Sofie B Grønseth

|Apr 23, 2021
Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39).

Kathleen N Moore, Michael Bookman, Jalid Sehouli

|Dec 29, 2020
Concordance Between Tumor and Germline BRCA Status in High-Grade Ovarian Carcinoma Patients in the Phase III PAOLA-1/ENGOT-ov25 Trial.

Céline Callens, Dominique Vaur, Isabelle Soubeyran

Pageof 1